GlassScriptPhysician profile
Lina Pilshchik
NPI 1235263948
$7,239.88
in general payments reported to CMS, 2019-2025
29 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,329 · 2020: $679 · 2021: $792 · 2022: $986 · 2023: $1,542 · 2024: $708 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,901.05 | 2019-2025 | |
| Myriad Women'S Health, INC. | $606.32 | 2023 | Myrisk |
| Astellas Pharma US INC | $500.99 | 2023-2025 | Veozah |
| Aspira Women'S Health INC | $431.16 | 2019-2022 | |
| Biogen, INC. | $400.33 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $375.27 | 2021-2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $349.75 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $347.70 | 2019-2023 | Balcoltra |
| Mayne Pharma Commercial LLC | $302.92 | 2021-2025 | |
| Exeltis, USA INC. | $275.55 | 2019-2025 | Slynd |
| Organon LLC | $162.03 | 2022-2025 | Nexplanon |
| Daiichi Sankyo INC. | $159.48 | 2022-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $157.71 | 2019-2025 | |
| Coopersurgical, INC. | $154.47 | 2019-2025 | Paragard T 380a |
| Myovant Sciences INC. | $131.05 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $130.86 | 2023-2024 | |
| Hologic Sales and Service, LLC | $124.73 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Glaxosmithkline, LLC. | $114.58 | 2023 | |
| Agile Therapeutics, INC. | $111.48 | 2021-2024 | Twirla |
| Lupin INC. | $90.10 | 2019-2020 | |
| Sage Therapeutics, LLC | $79.44 | 2020 | |
| Allergan, INC. | $66.54 | 2019 | |
| Merck Sharp & Dohme LLC | $55.94 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Scynexis, INC. | $45.97 | 2022 | |
| Roche Diagnostics Corporation | $43.22 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $36.75 | 2019 | |
| Bausch Health US, LLC | $33.84 | 2022 | |
| Mylan Pharmaceuticals INC. | $33.66 | 2020-2021 | |
| Medtronic, INC. | $16.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lina Pilshchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.